Onco-Summaries: Daily Oncology Updates at a Glance

09/08/2026

---

• US FDA Fast Track Designation for FAP‑targeted radionuclide conjugate GPN01530-2

---

US FDA Fast Track Designation for FAP‑targeted radionuclide conjugate GPN01530-2 (Ref)

Grand Pharmaceutical Group Limited announced that its investigational radionuclide-drug conjugate GPN01530-2, targeting fibroblast activating protein (FAP), has received Fast Track Designation from the US FDA

Return to Top